Bumetanide Versus Furosemide in Heart Failure

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Overview

Patients with NYHA FC II-III heart failure will be randomized in a cross-over fashion to 8 weeks of bumetanide versus furosemide therapy (equipotent dose), to test whether bumetanide therapy has a superior effect on insulin resistance compared to furosemide. Patients will be subject to a frequently sampled intravenous glucose tolerance test (FSIGT) with minimal model (MINMOD) analysis to assess insulin resistance and to a 6-minute walk test (6MWT) to assess functional capacity; patient recruitment and retention success, as well as medication adherence, will also be assessed.

Insulin resistance is common in patients with heart failure (HF) and is associated with a worse functional capacity and more severe symptoms of heart failure. The majority of HF patients take furosemide on at least a daily basis for symptom relief. Bumetanide is a loop diuretic with a similar therapeutic diuretic effect to furosemide. There is evidence from observational and small comparative trials that bumetanide has a significantly less deleterious effect on indirect measures of insulin resistance compared with furosemide. However, a formal comparison between the 2 drugs using rigorous measures of insulin resistance has never been conducted in patients with HF. If bumetanide can be demonstrated to have a similar diuretic and a superior (less deleterious) effect on insulin resistance in patients with HF, the potential exists for bumetanide to have a significantly reduced morbidity in patients with heart failure compared to furosemide. In order to prepare for such a study, the variance of the MINMOD-derived insulin resistance from the FSIGT (26), in this group of patient needs to be determined along with the feasibility of conducting such a study. Functional capacity will be determined by duplicate 6-minute walk tests.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Conditions

Heart Failure

Interventions

FurosemideDRUG

Current dose of furosemide will be maintained and equivalent dose bumetanide will be used following crossover

BumetanideDRUG

Equivalent dose to pre-existing furosemide will be used

furosemideDRUG

20mg to 80mg orally once or twice daily

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Men and women ≥18 years of age 2. NHYA FC II or III HF AND documented LVEF ≤40% within 6 months prior to study entry 3. Taking 20 mg to 80 mg furosemide orally once or twice per day 4. No changes to cardiac medications for 3 months prior to study entry and no anticipated changes of medications for the duration of the study 5. No changes to oral anti-diabetic medications (if applicable) for 3 months prior to study entry, and no anticipated changes for the duration of the study (metformin, sulphonylurea type, glitazone type) 6. Ability to provide written consent Exclusion Criteria: 1. Known sensitivity to bumetanide 2. Myocardial infarction, coronary angioplasty, coronary artery bypass surgery, admission for HF or unstable angina within a 3 month period prior to study recruitment 3. Planned coronary intervention within 6 months 4. Patients who are taking insulin 5. Patients with chronic renal (serum creatinine ≥ 200 μmol/L) or hepatic impairment (known cirrhosis or AST or ALT \> 1.5 x upper limit of normal)

Locations (1)

University Hospital, London Health Sciences Centre

London, Ontario, Canada

Outcomes

Primary Outcomes

Insulin resistance, as determined by frequently sampled intravenous glucose tolerance test with minimal model analysis (FSIGT MINMOD)

Time frame: 3 months

Secondary Outcomes

Fasting blood glucose

Time frame: 3 months

Glycosylated hemoglobin (HbA1c)

Time frame: 3 months

Serum creatinine, sodium, potassium, and chloride

Time frame: 3 months

Submaximal exercise capacity as determined by the 6-minute walk test

Time frame: 3 months

New York Heart Association Function Class heart failure (NYHA FC)

Time frame: 3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.